focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,775.00
Bid: 1,700.00
Ask: 1,779.00
Change: 0.00 (0.00%)
Spread: 79.00 (4.647%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,775.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET COMMENT: UK Stocks Trade Higher Despite Retail Sales Miss

Fri, 21st Feb 2014 10:47

LONDON (Alliance News) - The FTSE 100 is on track to post its sixth consecutive daily rise Friday, as weaker-than-expected UK retail sales and public finances data failed to dent the recent market positivity.

By mid-morning, the FTSE 100 is up 0.4% at 6,836.91, just over 30 points shy of its highest level in 2014, the FTSE 250 is up 0.3% at 16,415.65, and the AIM All-Share index is marginally higher at 882.99.

British retail sales declined more-than-expected in January. Including automotive fuel, retail sales fell 1.5% month-on-month, the first decline in three months, the Office for National Statistics said. Economists had been expecting a more modest 1% decrease, after the 2.5% rise in December.

At the same time, the Office of National Statistics published UK public finances data for January. The UK public sector net borrowing posted a surplus of GBP6.43 billion in January, having recorded a GBP9.03 billion deficit in December.

In the forex market, the pound has retaken the losses it made before the data was published. The currency was trading at a weekly low of USD1.661 at the time of the release, but is now at USD1.6668. Similarly, after dipping against the Swiss franc and the euro, sterling now trades at CHF1.4843 and EUR1.2161.

At the individual UK stock level, Royal Bank of Scotland, up 1.4%, is amongst the biggest risers in the FTSE 100. The group is preparing a dramatic retrenchment that would see it become a much smaller UK retail and commercial bank, a move that is expected to see staff numbers slashed by at least 30,000 in the coming years, the Financial Times reported Friday.

Shore Capital has reiterated its Buy recommendation, saying that the move is likely to result in a, "smaller but more efficient, higher return and less risky bank."

GlaxoSmithKline, up 1%, is another big riser. The drugs giant said that Incruse, a treatment for chronic obstructive pulmonary disease, had been recommended for marketing authorisation by the European Medicines Agency's committee for Medical Products for Human Use, a key step in getting approval for the drug.

The news comes after Anoro, another treatment for the disease, was also recommended for marketing authorisation by the committee on Thursday.

In the FTSE 250, Millennium & Copthorne Hotels and IP Group are the stand-out performers.

Millennium & Copthorne reported a pretax profit of GBP167.7 million for the fourth quarter of 2013, up from only GBP54.2 million a year earlier, and recorded a pretax profit of GBP263.6 million for the year as a whole, compared with a profit of GBP171.3 million in 2012.

IP Group, meanwhile, has jumped after it said its portfolio company, Xeros Ltd, intends to float on AIM to raise funds to bring its cleaning product to the laundry market.

Still to come in the data calendar Friday, US existing home sales data is released at 1500 GMT, before President of the Federal Reserve Bank of St. Louis James Bullard gives a speech at 1810 GMT.

By James Kemp; jameskemp@alliancenews.com; @jamespkemp

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.